Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDK4/6 Inhibitor Market Snapshot: New Drugs Jockey For A Piece Of The Multi-Billion Dollar Pie

Executive Summary

Pfizer's Ibrance has a strong lead in the CDK4/6 space, but Novartis' Kisqali and Lilly's Verzenio are looking to carve out their own niches, expand the category and move into earlier treatment settings. Another scramble is on as well, to answer the question: what comes next?

Advertisement

Related Content

Eight Things To Know From Novartis' Third Quarter Call
Pfizer Expands In Breast Cancer With Talazoparib Approval
Finance Watch: Lilly Completes Elanco Animal Health Spin-Out As New IPO Filings Keep Rising
Novartis' SOLAR-1 Study Shines on Alpelisib In Breast Cancer
Pharma Q2 Results Preview: Pfizer, Teva, Shire, Sanofi And Novo Nordisk
Pharma Q2 Results Preview: Lilly, Biogen, GSK And Gilead
Cosentyx Carries Novartis Sales But Kymriah Manufacturing Gives Cause For Concern
Novartis' New Oncology CEO Liz Barrett Charts A Course, But It Will Require Jump-Starting New Brands
Novartis Sets 'Flexible Pricing' For Kisqali To Compete Against Pfizer's Ibrance

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123285

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel